Background: The use of local anesthetics (LA) in patients with Brugada Syndrome (BrS) is still controversial, even though no large-scale study has confirmed a hazardous effect. This study’s main goal is to assess the occurrence of malignant arrhythmias or defibrillations in patients with BrS during the administration of local anesthetics and the 30 following days. The secondary aim was to investigate adverse events during hospitalization and the 30-day readmission and mortality rate. Methods: We performed a retrospective cohort study on patients with BrS who received regional anesthesia from January 1, 1996, to September 30, 2020. We analyzed the anesthetic charts and electronic medical records up to 30 days after each administration of local anesthetic. Results: We analyzed 47 procedures of patients with BrS who received locoregional anesthesia. These patients were divided into three groups: 27 in the peripheral nerve block (PNB) group, 13 in the epidural group, and 9 in the spinal group. One patient in the PNB group intraoperatively developed ventricular fibrillation after administration of ajmaline. No other events were recorded. Conclusion: Based on the analysis of our database, we conclude that using Ropivacaine for locoregional anesthesia and Bupivacaine for spinal anesthesia did not induce arrhythmias or other adverse events. No readmissions or mortalities were registered within 30 days.